查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
勝肽合成市場 - 2018-2028F 全球產業規模、佔有率、趨勢、機會和預測，按產品、技術、按應用、最終用戶、地區、競爭細分
市場調查報告書
商品編碼
1355180

勝肽合成市場 - 2018-2028F 全球產業規模、佔有率、趨勢、機會和預測，按產品、技術、按應用、最終用戶、地區、競爭細分

Peptide Synthesis Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F Segmented By Product, By Technology, By Application, By End-User, By Region, Competition
出版日期: | 出版商: TechSci Research | 英文 200 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2022 年，全球肽合成市場估值為42 億美元，預計在預測期內將出現強勁成長，到2028 年複合年成長率為5.8%。肽是透過一種氨基酸的羧基與一種氨基酸的羧基偶聯來合成的。另一個胺基酸分子的氨基。通常會採用保護措施來避免意外反應。化學勝肽合成通常從勝肽的羧基端開始，向氨基端進展，這與蛋白質生物合成的方向相反。勝肽作為高效和選擇性的訊號分子，與特定的細胞表面受體（例如離子通道或G蛋白偶聯受體（GPCR））結合，引發細胞內反應。其卓越的藥理學特徵和內在特性使勝肽成為開發新療法的理想起點。值得注意的是，勝肽由於其特異性而在人類中表現出卓越的安全性、耐受性和功效。與基於蛋白質的生物製藥相比，勝肽療法表現出較低的加工複雜性，導致生產成本更類似於小分子。

主要市場促進因素

增加在製藥業的使用

市場概況
預測期 2018-2028
2022 年市場規模 41907萬美元
2028 年市場規模 6.0215億美元
2023-2028 年複合年成長率 6.08%
成長最快的細分市場 製藥和生物技術公司
最大的市場 北美洲

肽是高效且有針對性的藥理成分，具有多種生物作用。它們廣泛的化學空間、顯著的生物活性和特異性，加上合成相對簡單、易於使用和低毒性，使勝肽成為活性藥物成分的有希望的候選者。肽可以被設計為專門針對體內的某些受體、酶或蛋白質，從而實現高度針對性和精確的治療干預。這種有針對性的方法降低了脫靶效應的風險並提高了治療效果。勝肽具有廣泛的治療應用，包括治療癌症、代謝失調、心血管疾病、自體免疫疾病和傳染病。

肽在糖尿病的應用

市場的顯著成長可歸因於消費者保健產業中勝肽的採用顯著增加。勝肽在治療各種生活方式障礙方面具有廣泛的應用，包括癌症、糖尿病和肥胖症。這些代謝和生活方式疾病的盛行率不斷上升，為勝肽療法在腫瘤學和代謝疾病中的應用提供了機會。例如，根據國際糖尿病聯盟發布的2021年統計數據，全球有5.37億成年人（20-79歲）患有糖尿病，佔糖尿病患者的十分之一。此外，同一消息來源報告稱，5.41 億成年人患有葡萄糖耐受性受損 (IGT)，使他們面臨患 2 型糖尿病的高風險。已知多種勝肽療法，例如胰高血糖素樣勝肽-1醯胺，可以刺激餐後胰島素分泌，並廣泛用於胰臟治療。因此，對肽類藥物的需求預計將隨著糖尿病患者數量的增加而成長，從而在整個預測期內推動市場發展。

專注於新的基於勝肽的治療：

人們對勝肽作為潛在療法及其在製藥、生物技術和診斷等各個領域的多樣化應用的興趣日益濃厚，導致研究活動不斷增加。研究人員正在探索新的基於勝肽的治療方法並開發適用於多種醫療狀況的勝肽藥物，從而推動了對勝肽合成的需求。勝肽類新藥的成功研發和批准引起了製藥業的熱情。隨著更多基於勝肽的療法獲得監管部門的批准，勝肽合成設備和服務的市場不斷擴大，以滿足這些創新藥物的需求。

由於研究活動的增加、新產品的批准以及研發資金的增加，勝肽合成市場經歷了顯著的成長。先進的勝肽合成儀在這一成長中發揮了至關重要的作用。值得注意的是，2021 年 4 月，ISSAR Pharma 宣布獲得基於勝肽的新化學實體 (NCE) 的許可，以及預研究新藥 (IND) 申請和一項美國專利。肽藥物的這些顯著發展預計將推動市場需求。

擴展診斷和成像應用

基於勝肽的生物感測器專門設計用於檢測生物樣品中的生物分子或分析物。這些生物感測器在早期疾病檢測、監測治療反應和測量各種生化參數方面具有巨大潛力。透過摻入對目標分子具有高親和力和選擇性的勝肽序列，可以確保準確和靈敏的檢測。

勝肽用於開發可與體內疾病相關標靶結合的顯影劑。這些顯影劑在分子影像技術中發揮至關重要的作用，例如正子斷層掃描（PET）、單光子發射電腦斷層掃描（SPECT）和磁振造影（MRI）。基於勝肽的影像劑提供疾病部位的非侵入性和有針對性的可視化，極大地有助於診斷和治療計劃。基於勝肽的生物感測器、成像劑和生物標記的進步在診斷應用中至關重要。對非侵入性和標靶診斷工具（包括基於勝肽的顯影劑和生物感測器）的需求不斷成長，正在推動市場成長。

主要市場挑戰

純化和品質控制

在勝肽合成過程中，可能會形成雜質和副反應，影響最終產物的純度。要實現高純度需要仔細最佳化合成條件以盡量減少雜質的形成。然而，維持高純度可能需要大量資源，需要大量的試劑、溶劑和專用設備。純化成本佔總生產費用。從小規模擴大到大規模勝肽合成對保持一致的純度水平提出了挑戰。反應動力學和傳質等因素在較大範圍內可能會有所不同，需要額外的製程最佳化。勝肽在研究和治療中的成功應用依賴於獲得高純度的勝肽。高效液相層析 (HPLC) 等純化方法可能非常耗時，並且需要對每個勝肽序列進行最佳化。確保合成勝肽的準確、一致和安全需要品質控制措施。滿足高品質標準並實施高效的純化製程對勝肽合成市場提出了挑戰。

監管問題

勝肽在治療心血管和神經系統疾病、腎衰竭和罕見疾病方面受到高度追捧。目前，市場上提供超過 100 種經 FDA 批准的勝肽類藥物。處於臨床試驗或臨床前研究階段的多肽藥物數量超過700個，拓展潛力大。這些以勝肽為基礎的藥物分為小分子和大分子生物製劑。然而，它們介於小分子和大蛋白質之間的獨特地位帶來了監管挑戰。雖然大多數這些藥物都是化學合成的，但它們的作用機制差異很大。

制定全面的監管規則來充分滿足具有不同作用模式的多種分子實體的安全和品質要求是一項複雜的任務。此類藥物缺乏既定的監管標準，使問題更加複雜。此外，美國食品藥物管理局 (FDA) 和歐洲藥品管理局 (EMA) 在勝肽類藥物的監管許可方面存在差異。 FDA 將勝肽類藥物歸類為小分子藥物，由 FDA 藥物評估和研究中心 (CDER) 負責，而 EMA 則傾向於採用集中方式而不是相互認可程序。

缺乏統一的監管指南阻礙了治療性勝肽獲得許可，限制了其應用領域。因此，它成為全球肽合成行業成長的重大障礙。

主要市場趨勢

擴大罕見疾病治療的機會

可以對勝肽進行策略性設計，以針對與罕見疾病相關的特定分子途徑或基因突變。這種以精確為導向的方法可以實現更有效和量身定做的治療干預措施。可以客製化勝肽來解決特定的罕見突變或基因變異，從而允許透過個人化醫療方法針對個別患者進行個人化治療。基於勝肽的療法通常提供非侵入性遞送選擇，這使得它們成為對侵入性手術耐受性有限的罕見疾病患者的有吸引力的選擇。監管機構為治療罕見疾病的藥物提供激勵措施和特殊指定，為公司在該領域進行研究和開發創造機會。

勝肽為治療罕見遺傳性疾病和孤兒疾病提供了有前景的解決方案。肽合成市場的成長為開發和製造針對這些病症的勝肽療法提供了機會。公司可以專注於設計和合成專門針對與罕見疾病相關的分子標靶的勝肽，從而解決未滿足的醫療需求。

勝肽在個人化醫療發展的應用

個體化治療的概念旨在實現最佳反應並最大化安全裕度以加強患者護理，這引起了人們對個別化治療的濃厚興趣。蛋白質體分析為破解不同組織（無論是健康組織還是患病組織）的分子譜提供了一種有吸引力且有效的方法。個人化蛋白質體學或蛋白質體學分析的出現代表了理解疾病路徑機制的重大進步。

在歐盟資助的 ElectroMed 計畫框架內，研究人員提議開發一個方便用戶使用的平台，以促進電化學引導的勝肽合成。這項創新平台將基於微流控多重系統，由軟體控制，從而促進蛋白質體學在個人化醫療中更廣泛的應用。

此外，利用奈米材料的無標記感測器將用於檢測和量化配體-受體複合物。這項技術進步將能夠自動注射配體合成所需的各種試劑，從而促進個人化治療背景下的個人化和受控勝肽合成。

對個人化醫療的投資不斷增加，很大程度上歸因於癌症和心血管疾病（CVD）等疾病盛行率的上升，以及對副作用最小的治療的需求不斷成長。個人化醫療有潛力提高醫療品質，同時降低成本。因此，肽合成市場的參與者將從客製化醫療領域的這些進步中受益。

細分市場洞察

技術洞察

在整個預測期內，液相肽合成（LPPS）一直是全球市場的主導部分，而固相肽合成則表現出最高的成長率。液相和固相勝肽合成的自動化和進步的整合極大地降低了勝肽合成的成本。因此，預計這將推動肽合成的全球採用，從而導致預測期內全球範圍內的收入增加。傳統研究表明，固相勝肽合成是一種適合 GMP 生產和 API 製程開發的方法，因為它在合成較小體積的長勝肽序列（超過 10 個胺基酸）方面具有成本效益。然而，值得注意的是，與固相勝肽合成相關的純化成本可能會增加任何生產規模的製造成本。另一方面，液相肽合成通常用於開發較短的勝肽序列和較大的體積。在某些情況下，混合方法用於大體積合成長序列。

最終使用者見解

2022年，製藥和生技產業佔收入佔有率的很大一部分。近年來，生物藥物、生物分子和生物製藥療法的開發大幅成長。因此，生物技術和製藥行業越來越關注勝肽和蛋白質作為藥物發現的目標。儘管蛋白質和勝肽具有一些具有巨大治療潛力的特徵，但它們具有根本的差異。該公司現在提供客製化勝肽合成、受保護的胺基酸、勝肽庫和試劑、活性藥物成分 (API) 生產、良好生產規範 (GMP) 製造以及非天然胺基酸和衍生物。勝肽的特殊要求推動了廣泛的研究，特別是在藥物傳輸系統領域。許多生命科學公司正在採用創新策略進行基於勝肽的藥物開發，以配製穩定、生物可利用且易於生產的組合物。給藥系統（例如鼻腔、腸胃外、控釋、經皮、脈衝和口服給藥）正在取得顯著進步，以增強勝肽給藥的有效性。與其他小分子藥物相比，勝肽通常表現出最小的毒性、高特異性和較少的毒理學挑戰，從而促進了治療藥物的開發，否則會帶來商業挑戰。

區域見解：

北美將在 2022 年成為市場的主導地區。其對全球市場的重大貢獻可歸因於主要參與者的強大影響力。此外，該地區對勝肽合成技術的認知不斷提高，以及對勝肽藥物商業規模生產的日益關注，進一步鞏固了其地位。

此外，預計亞太地區在預測期內將經歷最高的成長率。這可以歸因於該地區市場參與者的投資不斷增加、對創新肽治療的認知不斷提高、政府和患者醫療保健支出的增加、跨國公司與當地參與者之間的分銷合作以及低收入國家慢性病發病率的不斷上升。和中等收入國家。

主要市場參與者

  • 多勝肽組
  • 默克公司
  • 賽默飛世爾科技
  • 烯胺有限公司
  • 阿爾法化學
  • CEM公司
  • 金斯瑞
  • AAPP技術公司
  • 巴亨控股
  • AnaSpec 公司

可用的客製化：

全球勝肽合成市場報告根據給定的市場資料，技術科學研究根據公司的具體需求提供客製化服務。該報告可以使用以下自訂選項：

公司資訊

  • 其他市場參與者（最多五個）的詳細分析和概況分析。

目錄

第 1 章：產品概述

第 2 章：研究方法

第 3 章：執行摘要

第 4 章：客戶之聲

第 5 章：全球勝肽合成市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依產品（設備、試劑及消耗品、其他）
    • 依技術分類（固相勝肽合成（SPPS）、溶液相合成（SPS）、液相勝肽合成（LPPS）
    • 按應用（治療、診斷、研究）
    • 按最終用戶（製藥和生物技術公司、合約製造組織 (CMO)、學術和研究機構），
    • 按地區
    • 按公司分類 (2022)
  • 市場地圖

第 6 章：北美勝肽合成市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按產品分類
    • 依技術
    • 按應用
    • 按最終用戶
    • 按國家/地區
  • 北美：國家分析
    • 美國
    • 加拿大
    • 墨西哥

第 7 章：歐洲勝肽合成市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按產品分類
    • 依技術
    • 按應用
    • 按最終用戶
    • 按國家/地區
  • 歐洲：國家分析
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙

第 8 章：亞太地區勝肽合成市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按產品分類
    • 依技術
    • 按應用
    • 按最終用戶
    • 按國家/地區
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第 9 章：南美洲勝肽合成市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按產品分類
    • 依技術
    • 按應用
    • 按最終用戶
    • 按國家/地區
  • 南美洲：國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第10章 ：中東和非洲多肽合成市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按產品分類
    • 依技術
    • 按應用
    • 按最終用戶
    • 按國家/地區
  • MEA：國家分析
    • 南非勝肽合成
    • 沙烏地阿拉伯勝肽合成
    • 阿拉伯聯合大公國勝肽合成

第 11 章：市場動態

第 12 章：市場趨勢與發展

第 13 章：全球勝肽合成市場：SWOT 分析

第14章：競爭格局

  • 商業概覽
  • 產品供應
  • 最近的發展
  • 主要人員
  • SWOT分析
    • PolyPeptide Group
    • Merck KGaA
    • Thermo Fisher Scientific
    • Enamine Ltd.
    • Alfa Chemistry
    • CEM Corporation
    • GenScript
    • AAPPTec
    • Bachem Holding
    • AnaSpec, Inc.

第 15 章：策略建議

第 16 章：關於我們與免責聲明

簡介目錄
Product Code: 4555

The Global Peptide Synthesis Market was valued at USD 4.2 billion in 2022 and is projected to experience robust growth in the forecast period, with a CAGR of 5.8% through 2028. Peptides are synthesized through the coupling of the carboxyl group of one amino acid with the amino group of another amino acid molecule. Protective measures are commonly employed to avoid unintended reactions. Chemical peptide synthesis typically starts from the carboxyl end of the peptide, progressing towards the amino terminus, contrary to the direction of protein biosynthesis. Peptides act as highly effective and selective signaling molecules, binding to specific cell surface receptors such as ion channels or G protein-coupled receptors (GPCRs), triggering intracellular reactions. Their exceptional pharmacological profile and intrinsic characteristics make peptides an ideal starting point for the development of new therapies. Notably, peptides demonstrate exceptional safety, tolerability, and efficacy in humans due to their specificity. When compared to protein-based biopharmaceuticals, peptide therapeutics exhibit lower processing complexity, resulting in production costs more akin to small molecules.

Key Market Drivers

Increasing Use in Pharmaceutical Industry

Market Overview
Forecast Period2018-2028
Market Size 2022USD 419.07 Million
Market Size 2028USD 602.15 Million
CAGR 2023-20286.08%
Fastest Growing SegmentPharmaceutical and Biotechnology Companies
Largest MarketNorth America

Peptides are highly potent and targeted pharmacological ingredients, exhibiting a diverse range of biological actions. Their broad chemical space, remarkable biological activity, and specificity, coupled with their relative simplicity of synthesis, ready availability, and low toxicity, position peptides as promising candidates for active medicinal components. Peptides can be designed to specifically target certain receptors, enzymes, or proteins in the body, allowing for highly targeted and precise therapeutic interventions. This targeted approach reduces the risk of off-target effects and enhances therapeutic efficacy. Peptides have a wide range of therapeutic applications, including the treatment of cancer, metabolic disorders, cardiovascular diseases, autoimmune disorders, and infectious diseases.

Peptides make a significant contribution to the therapeutic landscape, particularly in the fields of oncology, diabetes, and obesity, generating billions of dollars in revenue. Moreover, the demand for peptides is steadily increasing for the treatment of renal failure, rare disorders, as well as cardiovascular and neurological conditions. Currently, there are over 100 peptide-based medications available, and with nearly 700 peptide medicines and therapeutic peptides in preclinical development, this number is projected to grow substantially.

Application of Peptides in Diabetes

The significant market growth can be attributed to the notable increase in the adoption of peptides in the consumer healthcare industries. Peptides have a diverse range of applications in treating various lifestyle disorders, including cancers, diabetes, and obesity. The rising prevalence of these metabolic and lifestyle disorders has opened up opportunities for the utilization of peptide therapeutics in oncology and metabolic disorders. For instance, according to the 2021 statistics published by the International Diabetes Federation, there were 537 million adults (20-79 years) living with diabetes worldwide, accounting for 1 in 10 individuals affected by diabetes. Additionally, the same source reported that 541 million adults had Impaired Glucose Tolerance (IGT), placing them at high risk of developing type 2 diabetes. Several peptide therapies, such as Glucagon-like peptide-1amide, are known to stimulate insulin secretion postprandially and are widely used in pancreatic therapy. As a result, the demand for peptide drugs is expected to rise in parallel with the increasing number of diabetic patients, thereby driving the market throughout the forecast period.

Focus on New Peptide-Based Treatments:

The growing interest in peptides as potential therapeutics and their diverse applications in various fields, such as pharmaceuticals, biotechnology, and diagnostics, has led to increased research activities. Researchers are exploring new peptide-based treatments and developing peptide drugs for a wide range of medical conditions, driving the demand for peptide synthesis. The successful development and approval of new peptide-based drugs have generated enthusiasm in the pharmaceutical industry. As more peptide-based therapies gain regulatory approval, the market for peptide synthesis equipment and services expands to meet the demand for these innovative drugs.

The peptide synthesis market has experienced significant growth, attributed to increased research activities, novel product approvals, and the rise in funding for research and development. Advanced peptide synthesizers have played a crucial role in this growth. Notably, in April 2021, ISSAR Pharma announced the licensing of their peptide-based New Chemical Entities (NCEs), along with pre-investigational new drug (IND) filing and a United States patent. These remarkable developments in peptide drugs are anticipated to drive market demand.

Expanding Applications in Diagnostics and Imaging

Peptide-based biosensors are specifically designed to detect biomolecules or analytes in biological samples. These biosensors have significant potential in early disease detection, monitoring treatment responses, and measuring various biochemical parameters. By incorporating peptide sequences with high affinity and selectivity for target molecules, accurate and sensitive detection can be ensured.

Peptides are utilized in the development of imaging agents that can bind to disease-related targets in the body. These imaging agents play a crucial role in molecular imaging techniques such as positron emission tomography (PET), single-photon emission computed tomography (SPECT), and magnetic resonance imaging (MRI). Offering non-invasive and targeted visualization of disease sites, peptide-based imaging agents greatly aid in diagnosis and treatment planning. The advancement of peptide-based biosensors, imaging agents, and biomarkers is pivotal in diagnostic applications. The growing demand for non-invasive and targeted diagnostic tools, including peptide-based imaging agents and biosensors, is driving market growth.

Key Market Challenges

Purification and Quality Control

During peptide synthesis, the formation of impurities and side reactions may occur, impacting the purity of the final product. Achieving high purity necessitates careful optimization of synthesis conditions to minimize impurity formation. However, maintaining high purity can be resource-intensive, requiring substantial amounts of reagents, solvents, and specialized equipment. The cost of purification contributes to overall production expenses. Scaling up from small-scale to large-scale peptide synthesis poses challenges in maintaining consistent purity levels. Factors such as reaction kinetics and mass transfer can differ at larger scales, requiring additional process optimization. The successful application of peptides in research and therapeutics relies on obtaining high-purity peptides. Purification methods like high-performance liquid chromatography (HPLC) can be time-consuming and require optimization for each peptide sequence. Ensuring accurate, consistent, and safe synthesized peptides calls for quality control measures. Meeting high-quality standards and implementing efficient purification processes presents a challenge for the peptide synthesis market.

Regulatory Issues

Peptides are highly sought after for the treatment of cardiovascular and neurological disorders, renal failure, and rare diseases. Currently, the market offers over 100 FDA-approved peptide-based medications. The number of peptide medicines in clinical trials or preclinical research surpasses 700, indicating significant potential for expansion. These peptide-based medications are classified as both small-molecule and large-molecule biologics. Yet, their unique position between small molecules and large proteins poses regulatory challenges. While most of these medications are chemically synthesized, their mechanisms of action vary widely.

Developing comprehensive regulatory rules that sufficiently address the safety and quality requirements for such a diverse range of molecular entities with distinct modes of action is a complex task. The absence of established regulatory criteria for this class of medications further complicates matters. Moreover, there is a disparity between the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) regarding the regulatory clearance of peptide-based medications. The FDA classifies peptide medications as small-molecule pharmaceuticals under the authority of the FDA's Center for Drug Evaluation and Research (CDER), while the EMA favors a centralized approach over the mutual recognition procedure.

This lack of uniform regulatory guidelines hampers the acquisition of permits for therapeutic peptides, limiting their application areas. Consequently, it serves as a significant barrier to the growth of the global peptide synthesis industry.

Key Market Trends

Expanding Opportunities in Therapeutics for Rare Diseases

Peptides can be strategically designed to target specific molecular pathways or genetic mutations associated with rare diseases. This precision-oriented approach enables more effective and tailored therapeutic interventions. Peptides can be customized to address specific rare mutations or genetic variants, allowing treatments to be personalized to individual patients through personalized medicine approaches. Peptide-based therapies often offer non-invasive delivery options, making them an attractive choice for patients with rare diseases who may have limited tolerance for invasive procedures. Regulatory agencies provide incentives and special designations for drugs developed to treat rare diseases, creating opportunities for companies to pursue research and development in this field.

Peptides offer promising solutions for the treatment of rare genetic disorders and orphan diseases. The growth of the peptide synthesis market presents an opportunity to develop and manufacture peptide-based therapeutics targeting these conditions. Companies can focus on designing and synthesizing peptides that specifically target molecular targets associated with rare diseases, thereby addressing unmet medical needs.

Utilization of Peptides in the Advancement of Personalized Medicine

The concept of individualized therapy aimed at achieving the best response and maximizing safety margins to enhance patient care has generated significant interest in personalized treatment. Proteomic analysis presents an appealing and effective approach for deciphering the molecular profiles of distinct tissues, whether healthy or diseased. The emergence of personalized proteomics or proteomic profiling represents a significant stride forward in understanding disease path mechanisms.

Within the framework of the EU-funded ElectroMed project, researchers have proposed the development of a user-friendly platform to facilitate electrochemically guided peptide synthesis. This innovative platform will be based on a microfluidic multiplexing system, controlled by software, thus promoting the broader application of proteomics in personalized medicine.

Additionally, label-free sensors utilizing nanomaterials will be employed to detect and quantify ligand-receptor complexes. This technological advancement will enable the automated injection of various reagents required for ligand synthesis, thereby facilitating personalized and controlled peptide synthesis in the context of personalized treatment.

The increasing investments in personalized medicine can be largely attributed to the rising prevalence of diseases such as cancer and cardiovascular disease (CVD), along with the growing demand for treatments with minimal adverse effects. Personalized medicine has the potential to enhance healthcare quality while simultaneously reducing costs. Consequently, players in the peptide synthesis market stand to benefit from these advancements in the field of customized medicine.

Segmental Insights

Technology Insights

Liquid-Phase Peptide Synthesis (LPPS) has been the dominant segment in the global market throughout the forecast period, while solid-phase peptide synthesis has exhibited the highest growth rate. The integration of automation and advancements in both liquid and solid-phase peptide synthesis has significantly contributed to cost reduction in peptide synthesis. As a result, it is anticipated that this will drive the global adoption of peptide synthesis, leading to increased revenue on a global scale during the forecast period. Conventional studies suggest that solid-phase peptide synthesis is a suitable approach for GMP manufacturing and API process development due to its cost-effectiveness in synthesizing long peptide sequences (more than 10 amino acids) with smaller volumes. However, it is important to note that purification costs associated with solid-phase peptide synthesis can potentially increase manufacturing costs at any scale of production. On the other hand, liquid-phase peptide synthesis is commonly employed for developing shorter peptide sequences and larger volumes. In certain cases, hybrid approaches are utilized for synthesizing long sequences at large volumes.

End User Insights

The pharmaceutical and biotechnology sector accounted for a significant portion of the revenue share in 2022. In recent years, there has been a substantial surge in the development of biologic drugs, biomolecules, and biopharmaceutical therapeutics. Consequently, the biotech and pharmaceutical industries are increasingly focusing on peptides and proteins as targets for drug discovery. Although proteins and peptides share several characteristics with substantial therapeutic potential, they possess fundamental distinctions. Companies are now providing tailored peptide synthesis, protected amino acids, peptide libraries and reagents, Active Pharmaceutical Ingredient (API) production, Good Manufacturing Practice (GMP) manufacturing, as well as unnatural amino acids and derivatives. The specialized requirements of peptides drive extensive research, particularly in the realm of drug delivery systems. Numerous life sciences companies are adopting innovative strategies for peptide-based drug development to formulate stable, bioavailable, and manufacturing-friendly compositions. Notable advancements in administration systems, such as nasal, parenteral, controlled-release, transdermal, pulsatile, and oral delivery, are being made to enhance the effectiveness of peptide administration. Peptides often exhibit minimal toxicity, high specificity, and fewer toxicological challenges compared to other small molecule drugs, thereby facilitating the development of therapeutics that would otherwise pose commercial challenges.

Regional Insights:

North America emerged as the dominant region in the market in 2022. Its significant contribution to the global market can be attributed to the strong presence of major players. Moreover, the region's heightened awareness regarding peptide synthesis technologies and increasing focus on commercial-scale production of peptide drugs have further reinforced its position.

Also, the Asia Pacific region is projected to experience the highest growth rate during the forecast period. This can be attributed to the growing investments by market players in the region, rising awareness about innovative peptide treatments, increased healthcare spending by governments and patients, collaborations between multinational companies and local players for distribution, and the escalating incidence of chronic diseases in low- and middle-income countries.

Key Market Players

  • PolyPeptide Group
  • Merck KGaA
  • Thermo Fisher Scientific
  • Enamine Ltd.
  • Alfa Chemistry
  • CEM Corporation
  • GenScript
  • AAPPTec
  • Bachem Holding
  • AnaSpec, Inc.

Report Scope:

In this report, the Global Peptide Synthesis Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Peptide Synthesis Market, By Product:

  • Equipment
  • Reagents and Consumables
  • Others

Peptide Synthesis Market, By Technology:

  • Solid-Phase Peptide Synthesis (SPPS)
  • Solution-Phase Synthesis (SPS)
  • Liquid-Phase Peptide Synthesis (LPPS)

Peptide Synthesis Market, By Application:

  • Therapeutics
  • Diagnosis
  • Research

Peptide Synthesis Market, By End User:

  • Pharmaceutical and Biotechnology Companies
  • Contract Manufacturing Organization (CMO)
  • Academic and Research Institutes

Peptide Synthesis Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Peptide Synthesis Market.

Available Customizations:

Global Peptide Synthesis market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

2. Research Methodology

3. Executive Summary

4. Voice of Customer

5. Global Peptide Synthesis Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product (Equipment, Reagents and Consumables, Others)
    • 5.2.2. By Technology (Solid-Phase Peptide Synthesis (SPPS), Solution-Phase Synthesis (SPS), Liquid-Phase Peptide Synthesis (LPPS)
    • 5.2.3. By Application (Therapeutics, Diagnosis, Research)
    • 5.2.4. By End-User (Pharmaceutical and Biotechnology Companies, Contract Manufacturing Organization (CMO), Academic and Research Institutes),
    • 5.2.5. By Region
    • 5.2.6. By Company (2022)
  • 5.3. Market Map

6. North America Peptide Synthesis Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product
    • 6.2.2. By Technology
    • 6.2.3. By Application
    • 6.2.4. By End User
    • 6.2.5. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Peptide Synthesis Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Product
        • 6.3.1.2.2. By Technology
        • 6.3.1.2.3. By Application
        • 6.3.1.2.4. By End User
    • 6.3.2. Canada Peptide Synthesis Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Product
        • 6.3.2.2.2. By Technology
        • 6.3.2.2.3. By Application
        • 6.3.2.2.4. By End User
    • 6.3.3. Mexico Peptide Synthesis Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Product
        • 6.3.3.2.2. By Technology
        • 6.3.3.2.3. By Application
        • 6.3.3.2.4. By End User

7. Europe Peptide Synthesis Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product
    • 7.2.2. By Technology
    • 7.2.3. By Application
    • 7.2.4. By End User
    • 7.2.5. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Peptide Synthesis Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product
        • 7.3.1.2.2. By Technology
        • 7.3.1.2.3. By Application
        • 7.3.1.2.4. By End User
    • 7.3.2. United Kingdom Peptide Synthesis Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product
        • 7.3.2.2.2. By Technology
        • 7.3.2.2.3. By Application
        • 7.3.2.2.4. By End User
    • 7.3.3. Italy Peptide Synthesis Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecasty
        • 7.3.3.2.1. By Product
        • 7.3.3.2.2. By Technology
        • 7.3.3.2.3. By Application
        • 7.3.3.2.4. By End User
    • 7.3.4. France Peptide Synthesis Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Product
        • 7.3.4.2.2. By Technology
        • 7.3.4.2.3. By Application
        • 7.3.4.2.4. By End User
    • 7.3.5. Spain Peptide Synthesis Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Product
        • 7.3.5.2.2. By Technology
        • 7.3.5.2.3. By Application
        • 7.3.5.2.4. By End User

8. Asia-Pacific Peptide Synthesis Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product
    • 8.2.2. By Technology
    • 8.2.3. By Application
    • 8.2.4. By End User
    • 8.2.5. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Peptide Synthesis Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product
        • 8.3.1.2.2. By Technology
        • 8.3.1.2.3. By Application
        • 8.3.1.2.4. By End User
    • 8.3.2. India Peptide Synthesis Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product
        • 8.3.2.2.2. By Technology
        • 8.3.2.2.3. By Application
        • 8.3.2.2.4. By End User
    • 8.3.3. Japan Peptide Synthesis Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product
        • 8.3.3.2.2. By Technology
        • 8.3.3.2.3. By Application
        • 8.3.3.2.4. By End User
    • 8.3.4. South Korea Peptide Synthesis Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Product
        • 8.3.4.2.2. By Technology
        • 8.3.4.2.3. By Application
        • 8.3.4.2.4. By End User
    • 8.3.5. Australia Peptide Synthesis Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Product
        • 8.3.5.2.2. By Technology
        • 8.3.5.2.3. By Application
        • 8.3.5.2.4. By End User

9. South America Peptide Synthesis Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product
    • 9.2.2. By Technology
    • 9.2.3. By Application
    • 9.2.4. By End User
    • 9.2.5. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Peptide Synthesis Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product
        • 9.3.1.2.2. By Technology
        • 9.3.1.2.3. By Application
        • 9.3.1.2.4. By End User
    • 9.3.2. Argentina Peptide Synthesis Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product
        • 9.3.2.2.2. By Technology
        • 9.3.2.2.3. By Application
        • 9.3.2.2.4. By End User
    • 9.3.3. Colombia Peptide Synthesis Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product
        • 9.3.3.2.2. By Technology
        • 9.3.3.2.3. By Application
        • 9.3.3.2.4. By End User

10. Middle East and Africa Peptide Synthesis Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product
    • 10.2.2. By Technology
    • 10.2.3. By Application
    • 10.2.4. By End User
    • 10.2.5. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Peptide Synthesis Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Product
        • 10.3.1.2.2. By Technology
        • 10.3.1.2.3. By Application
        • 10.3.1.2.4. By End User
    • 10.3.2. Saudi Arabia Peptide Synthesis Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Product
        • 10.3.2.2.2. By Technology
        • 10.3.2.2.3. By Application
        • 10.3.2.2.4. By End User
    • 10.3.3. UAE Peptide Synthesis Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Product
        • 10.3.3.2.2. By Technology
        • 10.3.3.2.3. By Application
        • 10.3.3.2.4. By End User

11. Market Dynamics

12. Market Trends & Developments

13. Global Peptide Synthesis Market: SWOT Analysis

14. Competitive Landscape

  • 14.1. Business Overview
  • 14.2. Product Offerings
  • 14.3. Recent Developments
  • 14.4. Key Personnel
  • 14.5. SWOT Analysis
    • 14.5.1. PolyPeptide Group
    • 14.5.2. Merck KGaA
    • 14.5.3. Thermo Fisher Scientific
    • 14.5.4. Enamine Ltd.
    • 14.5.5. Alfa Chemistry
    • 14.5.6. CEM Corporation
    • 14.5.7. GenScript
    • 14.5.8. AAPPTec
    • 14.5.9. Bachem Holding
    • 14.5.10. AnaSpec, Inc.

15. Strategic Recommendations

16. About Us & Disclaimer